A new white paper from Xcenda and the National Pharmaceutical Council (NPC) highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population coverage decisions for formularies and care pathways. Recognizing the importance of these decisions on patients’ lives, it’s not surprising that payers and providers use multiple sources of information that offer a more complete picture about a treatment and its outcomes and impact on cost and quality, rather than just a snapshot.

As the healthcare market becomes increasingly driven to optimize outcomes and reduce waste, personalized medicine (PM) holds a great deal of promise for stakeholders across the continuum. Yet despite the allure of improving quality of care by targeting therapy, predicting disease course, mitigating risk and efficiently using scarce resources, personalized medicine still faces a number of barriers to widespread adoption.

Fueled by technological advances, scientific breakthroughs and significant financial investments, precision medicine (PM) has emerged as a promising approach to disease prevention and treatment. A multi-faceted solution to patient care, PM can improve patient outcomes and increase the effectiveness of the nation's healthcare system by targeting therapy, predicting disease course and reducing the waste of resources - delivering the right treatment to the right person at the right time. However, the continued growth and success of PM across the healthcare landscape relies, at least in part, on whether physicians are able to integrate the approach into their clinical practices.